$7.80-0.77 (-8.99%)
eXoZymes, Inc.
eXoZymes, Inc. in the Healthcare sector is trading at $7.80. The stock is currently near its 52-week low of $7.08, remaining 30.7% below its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the distress zone. Risk note: RSI 22 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 45/100 suggests a balanced risk-reward profile.
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
eXoZymes, Inc. operates as a development stage biotechnology company. It focuses on the development of enzyme modules and cell-free exozyme biosolutions for synthetic biology manufacturing. The company was formerly known as Invizyne Technologies, Inc...
Discover how MDB Capital Holdings LLC (MDBH) is leveraging AI and strategic investments to navigate market challenges and drive future growth.
EXoZymes Inc (EXOZ) showcases its innovative biomanufacturing platform and strategic focus on NCT and cannabinoids, while navigating financial hurdles and market skepticism.
Executives at eXoZymes (NASDAQ:EXOZ) used the company’s latest investor call to outline how management is prioritizing a narrower set of commercial opportunities, led by its NCT program and a cannabinoid pipeline, while preparing for a new financing round and continuing to develop its cell-free biom
EXoZymes Inc (EXOZ) showcases innovative breakthroughs and strategic partnerships while navigating financial hurdles and regulatory risks.
US stocks look set to open higher in Wednesday's trading session after a key inflation measure unexp